BOLD earnings analysis
What we found in BOLD's 10-Q: the parts that mattered, the offsets in the same document, and what the company said about what comes next.
Our reading of the filing · Free to read, no account needed
Boundless Bio reported a net loss of $13.6 million for Q1 2026, an improvement from a $15.8 million net loss in Q1 2025, indicating a positive trend in cost management. Operating expenses decreased, driven primarily by lower R&D expenses. The company's focus on the BBI-940 program signals future potential despite ongoing losses.
The parts that mattered.
Pulled out of the filing itself, with the figures the company reported.
- Reduced Net Loss
- Net loss improved to $13.6 million from $15.8 million year-over-year.
- Lower R&D Expenses
- R&D expenses decreased by $2.4 million to $9.7 million compared to Q1 2025.
- Improved Operating Expenses
- Total operating expenses fell to $14.5 million from $17.3 million, a decrease of $2.9 million.
- Cash Position Remains Strong
- Cash, cash equivalents, and short-term investments stand at $92.8 million as of March 31, 2026.
- Initiated KOMODO-1 Trial
- The company commenced the Phase 1 KOMODO-1 trial for BBI-940 in February 2026.
- Future Cash Runway Extended
- Current cash runway is projected to last into the second half of 2028.
And the other side of it.
The offsets in the same document — the things a summary that only listed the good news would have left out.
- Accumulated Deficit
- Accumulated deficit reached $273.2 million as of March 31, 2026.
- Dependency on Clinical Trials
- The company has not generated any revenue and remains reliant on successful clinical trial outcomes.
- Need for Additional Funding
- Future operations will require additional funding, with no committed sources of capital identified.
What they reported.
What the company itself reported, taken out of the document.
- Earnings per share
- $-0.6
What they said about what is next.
Outlook deferred to future earnings call.
The filing reads better than the one before it.
What came before.
- 10-K · March 9, 2026
- Boundless Bio remains a pre-revenue, clinical-stage oncology company focused on ecDNA-directed therapeutics (ecDTx). The company initiated a first-in-human Phase 1 KOMODO-1 trial of lead candidate BBI-940 in February…
- 10-Q · November 5, 2025
- Boundless Bio reported no revenue for Q3 2025 and a narrower net loss of $13.9M (EPS -$0.62) versus a loss of $16.5M (EPS -$0.74) in the prior-year quarter. Operating expenses fell 19% year-over-year to $15.1M driven by…
- 10-Q · August 5, 2025
- Boundless Bio remains pre-revenue but showed modest operating improvement in Q2 2025: quarterly net loss narrowed to $15,675 (three months ended June 30, 2025) from $16,976 a year earlier and EPS improved to $(0.70)…
- 10-Q · May 9, 2025
- Boundless Bio remains a pre-revenue clinical-stage company with $138.3M of cash, cash equivalents and short-term investments as of March 31, 2025 and management believes that amount is sufficient to fund operations for…
This is our reading of a public filing, not the filing. Read the original on SEC.gov · Educational only. Nothing here is investment advice.
Read the next one first.
We read every filing BOLD makes the day it lands, and put it next to what the options market did about it. Members get both, and an alert when a filing arrives.
Cancel anytime · Month to month · Switch tiers whenever